line_item,period,value,symbol
Tax Effect Of Unusual Items,2025-03-31 00:00:00,0.0,BALPHARMA.NS
Tax Rate For Calcs,2025-03-31 00:00:00,0.3,BALPHARMA.NS
Normalized EBITDA,2025-03-31 00:00:00,317628000.0,BALPHARMA.NS
Total Unusual Items,2025-03-31 00:00:00,0.0,BALPHARMA.NS
Total Unusual Items Excluding Goodwill,2025-03-31 00:00:00,0.0,BALPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2025-03-31 00:00:00,72154000.0,BALPHARMA.NS
Reconciled Depreciation,2025-03-31 00:00:00,97709000.0,BALPHARMA.NS
Reconciled Cost Of Revenue,2025-03-31 00:00:00,1578934000.0,BALPHARMA.NS
EBITDA,2025-03-31 00:00:00,317628000.0,BALPHARMA.NS
EBIT,2025-03-31 00:00:00,219919000.0,BALPHARMA.NS
Net Interest Income,2025-03-31 00:00:00,-168544000.0,BALPHARMA.NS
Interest Expense,2025-03-31 00:00:00,168544000.0,BALPHARMA.NS
Interest Income,2025-03-31 00:00:00,,BALPHARMA.NS
Normalized Income,2025-03-31 00:00:00,72154000.0,BALPHARMA.NS
Net Income From Continuing And Discontinued Operation,2025-03-31 00:00:00,72154000.0,BALPHARMA.NS
Total Expenses,2025-03-31 00:00:00,2832943000.0,BALPHARMA.NS
Rent Expense Supplemental,2025-03-31 00:00:00,,BALPHARMA.NS
Diluted Average Shares,2025-03-31 00:00:00,15823246.0,BALPHARMA.NS
Basic Average Shares,2025-03-31 00:00:00,15823246.0,BALPHARMA.NS
Diluted EPS,2025-03-31 00:00:00,4.56,BALPHARMA.NS
Basic EPS,2025-03-31 00:00:00,4.56,BALPHARMA.NS
Diluted NI Availto Com Stockholders,2025-03-31 00:00:00,72154000.0,BALPHARMA.NS
Net Income Common Stockholders,2025-03-31 00:00:00,72154000.0,BALPHARMA.NS
Otherunder Preferred Stock Dividend,2025-03-31 00:00:00,0.0,BALPHARMA.NS
Net Income,2025-03-31 00:00:00,72154000.0,BALPHARMA.NS
Minority Interests,2025-03-31 00:00:00,-213000.0,BALPHARMA.NS
Net Income Including Noncontrolling Interests,2025-03-31 00:00:00,72367000.0,BALPHARMA.NS
Net Income Continuous Operations,2025-03-31 00:00:00,72367000.0,BALPHARMA.NS
Tax Provision,2025-03-31 00:00:00,-20992000.0,BALPHARMA.NS
Pretax Income,2025-03-31 00:00:00,51375000.0,BALPHARMA.NS
Other Non Operating Income Expenses,2025-03-31 00:00:00,22029000.0,BALPHARMA.NS
Special Income Charges,2025-03-31 00:00:00,0.0,BALPHARMA.NS
Other Special Charges,2025-03-31 00:00:00,,BALPHARMA.NS
Write Off,2025-03-31 00:00:00,,BALPHARMA.NS
Net Non Operating Interest Income Expense,2025-03-31 00:00:00,-168544000.0,BALPHARMA.NS
Total Other Finance Cost,2025-03-31 00:00:00,,BALPHARMA.NS
Interest Expense Non Operating,2025-03-31 00:00:00,168544000.0,BALPHARMA.NS
Interest Income Non Operating,2025-03-31 00:00:00,,BALPHARMA.NS
Operating Income,2025-03-31 00:00:00,197890000.0,BALPHARMA.NS
Operating Expense,2025-03-31 00:00:00,1254009000.0,BALPHARMA.NS
Other Operating Expenses,2025-03-31 00:00:00,532295000.0,BALPHARMA.NS
Depreciation And Amortization In Income Statement,2025-03-31 00:00:00,97709000.0,BALPHARMA.NS
Amortization,2025-03-31 00:00:00,,BALPHARMA.NS
Depreciation Income Statement,2025-03-31 00:00:00,97709000.0,BALPHARMA.NS
Research And Development,2025-03-31 00:00:00,,BALPHARMA.NS
Selling General And Administration,2025-03-31 00:00:00,,BALPHARMA.NS
Selling And Marketing Expense,2025-03-31 00:00:00,,BALPHARMA.NS
General And Administrative Expense,2025-03-31 00:00:00,,BALPHARMA.NS
Rent And Landing Fees,2025-03-31 00:00:00,,BALPHARMA.NS
Gross Profit,2025-03-31 00:00:00,1451899000.0,BALPHARMA.NS
Cost Of Revenue,2025-03-31 00:00:00,1578934000.0,BALPHARMA.NS
Total Revenue,2025-03-31 00:00:00,3030833000.0,BALPHARMA.NS
Operating Revenue,2025-03-31 00:00:00,3030833000.0,BALPHARMA.NS
Tax Effect Of Unusual Items,2024-03-31 00:00:00,0.0,BALPHARMA.NS
Tax Rate For Calcs,2024-03-31 00:00:00,0.177023,BALPHARMA.NS
Normalized EBITDA,2024-03-31 00:00:00,336008000.0,BALPHARMA.NS
Total Unusual Items,2024-03-31 00:00:00,0.0,BALPHARMA.NS
Total Unusual Items Excluding Goodwill,2024-03-31 00:00:00,0.0,BALPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2024-03-31 00:00:00,73922000.0,BALPHARMA.NS
Reconciled Depreciation,2024-03-31 00:00:00,100711000.0,BALPHARMA.NS
Reconciled Cost Of Revenue,2024-03-31 00:00:00,1917519000.0,BALPHARMA.NS
EBITDA,2024-03-31 00:00:00,336008000.0,BALPHARMA.NS
EBIT,2024-03-31 00:00:00,235297000.0,BALPHARMA.NS
Net Interest Income,2024-03-31 00:00:00,-144823000.0,BALPHARMA.NS
Interest Expense,2024-03-31 00:00:00,144823000.0,BALPHARMA.NS
Interest Income,2024-03-31 00:00:00,5596000.0,BALPHARMA.NS
Normalized Income,2024-03-31 00:00:00,73922000.0,BALPHARMA.NS
Net Income From Continuing And Discontinued Operation,2024-03-31 00:00:00,73922000.0,BALPHARMA.NS
Total Expenses,2024-03-31 00:00:00,3185383000.0,BALPHARMA.NS
Rent Expense Supplemental,2024-03-31 00:00:00,10492000.0,BALPHARMA.NS
Diluted Average Shares,2024-03-31 00:00:00,14963968.0,BALPHARMA.NS
Basic Average Shares,2024-03-31 00:00:00,14963968.0,BALPHARMA.NS
Diluted EPS,2024-03-31 00:00:00,4.94,BALPHARMA.NS
Basic EPS,2024-03-31 00:00:00,4.94,BALPHARMA.NS
Diluted NI Availto Com Stockholders,2024-03-31 00:00:00,73922000.0,BALPHARMA.NS
Net Income Common Stockholders,2024-03-31 00:00:00,73922000.0,BALPHARMA.NS
Otherunder Preferred Stock Dividend,2024-03-31 00:00:00,0.0,BALPHARMA.NS
Net Income,2024-03-31 00:00:00,73922000.0,BALPHARMA.NS
Minority Interests,2024-03-31 00:00:00,-535000.0,BALPHARMA.NS
Net Income Including Noncontrolling Interests,2024-03-31 00:00:00,74458000.0,BALPHARMA.NS
Net Income Continuous Operations,2024-03-31 00:00:00,74458000.0,BALPHARMA.NS
Tax Provision,2024-03-31 00:00:00,16016000.0,BALPHARMA.NS
Pretax Income,2024-03-31 00:00:00,90474000.0,BALPHARMA.NS
Other Non Operating Income Expenses,2024-03-31 00:00:00,28482000.0,BALPHARMA.NS
Special Income Charges,2024-03-31 00:00:00,0.0,BALPHARMA.NS
Other Special Charges,2024-03-31 00:00:00,-827000.0,BALPHARMA.NS
Write Off,2024-03-31 00:00:00,,BALPHARMA.NS
Net Non Operating Interest Income Expense,2024-03-31 00:00:00,-144823000.0,BALPHARMA.NS
Total Other Finance Cost,2024-03-31 00:00:00,25364000.0,BALPHARMA.NS
Interest Expense Non Operating,2024-03-31 00:00:00,144823000.0,BALPHARMA.NS
Interest Income Non Operating,2024-03-31 00:00:00,5596000.0,BALPHARMA.NS
Operating Income,2024-03-31 00:00:00,206813000.0,BALPHARMA.NS
Operating Expense,2024-03-31 00:00:00,1267864000.0,BALPHARMA.NS
Other Operating Expenses,2024-03-31 00:00:00,562391000.0,BALPHARMA.NS
Depreciation And Amortization In Income Statement,2024-03-31 00:00:00,100711000.0,BALPHARMA.NS
Amortization,2024-03-31 00:00:00,39204000.0,BALPHARMA.NS
Depreciation Income Statement,2024-03-31 00:00:00,100711000.0,BALPHARMA.NS
Research And Development,2024-03-31 00:00:00,,BALPHARMA.NS
Selling General And Administration,2024-03-31 00:00:00,221689000.0,BALPHARMA.NS
Selling And Marketing Expense,2024-03-31 00:00:00,179009000.0,BALPHARMA.NS
General And Administrative Expense,2024-03-31 00:00:00,42680000.0,BALPHARMA.NS
Rent And Landing Fees,2024-03-31 00:00:00,10492000.0,BALPHARMA.NS
Gross Profit,2024-03-31 00:00:00,1474677000.0,BALPHARMA.NS
Cost Of Revenue,2024-03-31 00:00:00,1917519000.0,BALPHARMA.NS
Total Revenue,2024-03-31 00:00:00,3392196000.0,BALPHARMA.NS
Operating Revenue,2024-03-31 00:00:00,3392196000.0,BALPHARMA.NS
Tax Effect Of Unusual Items,2023-03-31 00:00:00,315770.4,BALPHARMA.NS
Tax Rate For Calcs,2023-03-31 00:00:00,0.2376,BALPHARMA.NS
Normalized EBITDA,2023-03-31 00:00:00,242399000.0,BALPHARMA.NS
Total Unusual Items,2023-03-31 00:00:00,1329000.0,BALPHARMA.NS
Total Unusual Items Excluding Goodwill,2023-03-31 00:00:00,1329000.0,BALPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2023-03-31 00:00:00,25717000.0,BALPHARMA.NS
Reconciled Depreciation,2023-03-31 00:00:00,91283000.0,BALPHARMA.NS
Reconciled Cost Of Revenue,2023-03-31 00:00:00,1762439000.0,BALPHARMA.NS
EBITDA,2023-03-31 00:00:00,243728000.0,BALPHARMA.NS
EBIT,2023-03-31 00:00:00,152445000.0,BALPHARMA.NS
Net Interest Income,2023-03-31 00:00:00,-120825000.0,BALPHARMA.NS
Interest Expense,2023-03-31 00:00:00,104960000.0,BALPHARMA.NS
Interest Income,2023-03-31 00:00:00,2313000.0,BALPHARMA.NS
Normalized Income,2023-03-31 00:00:00,24703770.4,BALPHARMA.NS
Net Income From Continuing And Discontinued Operation,2023-03-31 00:00:00,25717000.0,BALPHARMA.NS
Total Expenses,2023-03-31 00:00:00,2841623000.0,BALPHARMA.NS
Rent Expense Supplemental,2023-03-31 00:00:00,7636000.0,BALPHARMA.NS
Diluted Average Shares,2023-03-31 00:00:00,15690000.0,BALPHARMA.NS
Basic Average Shares,2023-03-31 00:00:00,15690000.0,BALPHARMA.NS
Diluted EPS,2023-03-31 00:00:00,1.67,BALPHARMA.NS
Basic EPS,2023-03-31 00:00:00,1.67,BALPHARMA.NS
Diluted NI Availto Com Stockholders,2023-03-31 00:00:00,25717000.0,BALPHARMA.NS
Net Income Common Stockholders,2023-03-31 00:00:00,25717000.0,BALPHARMA.NS
Otherunder Preferred Stock Dividend,2023-03-31 00:00:00,0.0,BALPHARMA.NS
Net Income,2023-03-31 00:00:00,25717000.0,BALPHARMA.NS
Minority Interests,2023-03-31 00:00:00,-475000.0,BALPHARMA.NS
Net Income Including Noncontrolling Interests,2023-03-31 00:00:00,26193000.0,BALPHARMA.NS
Net Income Continuous Operations,2023-03-31 00:00:00,26193000.0,BALPHARMA.NS
Tax Provision,2023-03-31 00:00:00,21292000.0,BALPHARMA.NS
Pretax Income,2023-03-31 00:00:00,47485000.0,BALPHARMA.NS
Other Non Operating Income Expenses,2023-03-31 00:00:00,5764000.0,BALPHARMA.NS
Special Income Charges,2023-03-31 00:00:00,1329000.0,BALPHARMA.NS
Other Special Charges,2023-03-31 00:00:00,-1329000.0,BALPHARMA.NS
Write Off,2023-03-31 00:00:00,0.0,BALPHARMA.NS
Net Non Operating Interest Income Expense,2023-03-31 00:00:00,-120825000.0,BALPHARMA.NS
Total Other Finance Cost,2023-03-31 00:00:00,18178000.0,BALPHARMA.NS
Interest Expense Non Operating,2023-03-31 00:00:00,104960000.0,BALPHARMA.NS
Interest Income Non Operating,2023-03-31 00:00:00,2313000.0,BALPHARMA.NS
Operating Income,2023-03-31 00:00:00,175450000.0,BALPHARMA.NS
Operating Expense,2023-03-31 00:00:00,1079184000.0,BALPHARMA.NS
Other Operating Expenses,2023-03-31 00:00:00,265895000.0,BALPHARMA.NS
Depreciation And Amortization In Income Statement,2023-03-31 00:00:00,91282000.0,BALPHARMA.NS
Amortization,2023-03-31 00:00:00,19677000.0,BALPHARMA.NS
Depreciation Income Statement,2023-03-31 00:00:00,71605000.0,BALPHARMA.NS
Research And Development,2023-03-31 00:00:00,0.0,BALPHARMA.NS
Selling General And Administration,2023-03-31 00:00:00,181977000.0,BALPHARMA.NS
Selling And Marketing Expense,2023-03-31 00:00:00,147741000.0,BALPHARMA.NS
General And Administrative Expense,2023-03-31 00:00:00,34236000.0,BALPHARMA.NS
Rent And Landing Fees,2023-03-31 00:00:00,7636000.0,BALPHARMA.NS
Gross Profit,2023-03-31 00:00:00,1254634000.0,BALPHARMA.NS
Cost Of Revenue,2023-03-31 00:00:00,1762439000.0,BALPHARMA.NS
Total Revenue,2023-03-31 00:00:00,3017073000.0,BALPHARMA.NS
Operating Revenue,2023-03-31 00:00:00,3017073000.0,BALPHARMA.NS
Tax Effect Of Unusual Items,2022-03-31 00:00:00,6468235.2,BALPHARMA.NS
Tax Rate For Calcs,2022-03-31 00:00:00,0.2884,BALPHARMA.NS
Normalized EBITDA,2022-03-31 00:00:00,248548000.0,BALPHARMA.NS
Total Unusual Items,2022-03-31 00:00:00,22428000.0,BALPHARMA.NS
Total Unusual Items Excluding Goodwill,2022-03-31 00:00:00,22428000.0,BALPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2022-03-31 00:00:00,56115000.0,BALPHARMA.NS
Reconciled Depreciation,2022-03-31 00:00:00,90401000.0,BALPHARMA.NS
Reconciled Cost Of Revenue,2022-03-31 00:00:00,1678183000.0,BALPHARMA.NS
EBITDA,2022-03-31 00:00:00,270976000.0,BALPHARMA.NS
EBIT,2022-03-31 00:00:00,180575000.0,BALPHARMA.NS
Net Interest Income,2022-03-31 00:00:00,-105387000.0,BALPHARMA.NS
Interest Expense,2022-03-31 00:00:00,88752000.0,BALPHARMA.NS
Interest Income,2022-03-31 00:00:00,3701000.0,BALPHARMA.NS
Normalized Income,2022-03-31 00:00:00,40155235.2,BALPHARMA.NS
Net Income From Continuing And Discontinued Operation,2022-03-31 00:00:00,56115000.0,BALPHARMA.NS
Total Expenses,2022-03-31 00:00:00,2646392000.0,BALPHARMA.NS
Rent Expense Supplemental,2022-03-31 00:00:00,5644000.0,BALPHARMA.NS
Diluted Average Shares,2022-03-31 00:00:00,14822000.0,BALPHARMA.NS
Basic Average Shares,2022-03-31 00:00:00,14822000.0,BALPHARMA.NS
Diluted EPS,2022-03-31 00:00:00,3.785926,BALPHARMA.NS
Basic EPS,2022-03-31 00:00:00,3.785926,BALPHARMA.NS
Diluted NI Availto Com Stockholders,2022-03-31 00:00:00,56115000.0,BALPHARMA.NS
Net Income Common Stockholders,2022-03-31 00:00:00,56115000.0,BALPHARMA.NS
Otherunder Preferred Stock Dividend,2022-03-31 00:00:00,0.0,BALPHARMA.NS
Net Income,2022-03-31 00:00:00,56115000.0,BALPHARMA.NS
Minority Interests,2022-03-31 00:00:00,-934000.0,BALPHARMA.NS
Net Income Including Noncontrolling Interests,2022-03-31 00:00:00,57048000.0,BALPHARMA.NS
Net Income Continuous Operations,2022-03-31 00:00:00,57048000.0,BALPHARMA.NS
Tax Provision,2022-03-31 00:00:00,34775000.0,BALPHARMA.NS
Pretax Income,2022-03-31 00:00:00,91823000.0,BALPHARMA.NS
Other Non Operating Income Expenses,2022-03-31 00:00:00,17338000.0,BALPHARMA.NS
Special Income Charges,2022-03-31 00:00:00,22428000.0,BALPHARMA.NS
Other Special Charges,2022-03-31 00:00:00,-22428000.0,BALPHARMA.NS
Write Off,2022-03-31 00:00:00,0.0,BALPHARMA.NS
Net Non Operating Interest Income Expense,2022-03-31 00:00:00,-105387000.0,BALPHARMA.NS
Total Other Finance Cost,2022-03-31 00:00:00,20336000.0,BALPHARMA.NS
Interest Expense Non Operating,2022-03-31 00:00:00,88752000.0,BALPHARMA.NS
Interest Income Non Operating,2022-03-31 00:00:00,3701000.0,BALPHARMA.NS
Operating Income,2022-03-31 00:00:00,150597000.0,BALPHARMA.NS
Operating Expense,2022-03-31 00:00:00,968209000.0,BALPHARMA.NS
Other Operating Expenses,2022-03-31 00:00:00,230550000.0,BALPHARMA.NS
Depreciation And Amortization In Income Statement,2022-03-31 00:00:00,90401000.0,BALPHARMA.NS
Amortization,2022-03-31 00:00:00,14684000.0,BALPHARMA.NS
Depreciation Income Statement,2022-03-31 00:00:00,75717000.0,BALPHARMA.NS
Research And Development,2022-03-31 00:00:00,0.0,BALPHARMA.NS
Selling General And Administration,2022-03-31 00:00:00,175223000.0,BALPHARMA.NS
Selling And Marketing Expense,2022-03-31 00:00:00,148169000.0,BALPHARMA.NS
General And Administrative Expense,2022-03-31 00:00:00,27054000.0,BALPHARMA.NS
Rent And Landing Fees,2022-03-31 00:00:00,5644000.0,BALPHARMA.NS
Gross Profit,2022-03-31 00:00:00,1118806000.0,BALPHARMA.NS
Cost Of Revenue,2022-03-31 00:00:00,1678183000.0,BALPHARMA.NS
Total Revenue,2022-03-31 00:00:00,2796989000.0,BALPHARMA.NS
Operating Revenue,2022-03-31 00:00:00,2796989000.0,BALPHARMA.NS
Tax Effect Of Unusual Items,2021-03-31 00:00:00,,BALPHARMA.NS
Tax Rate For Calcs,2021-03-31 00:00:00,,BALPHARMA.NS
Normalized EBITDA,2021-03-31 00:00:00,,BALPHARMA.NS
Total Unusual Items,2021-03-31 00:00:00,,BALPHARMA.NS
Total Unusual Items Excluding Goodwill,2021-03-31 00:00:00,,BALPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2021-03-31 00:00:00,,BALPHARMA.NS
Reconciled Depreciation,2021-03-31 00:00:00,,BALPHARMA.NS
Reconciled Cost Of Revenue,2021-03-31 00:00:00,,BALPHARMA.NS
EBITDA,2021-03-31 00:00:00,,BALPHARMA.NS
EBIT,2021-03-31 00:00:00,,BALPHARMA.NS
Net Interest Income,2021-03-31 00:00:00,,BALPHARMA.NS
Interest Expense,2021-03-31 00:00:00,,BALPHARMA.NS
Interest Income,2021-03-31 00:00:00,3142000.0,BALPHARMA.NS
Normalized Income,2021-03-31 00:00:00,,BALPHARMA.NS
Net Income From Continuing And Discontinued Operation,2021-03-31 00:00:00,,BALPHARMA.NS
Total Expenses,2021-03-31 00:00:00,,BALPHARMA.NS
Rent Expense Supplemental,2021-03-31 00:00:00,6832000.0,BALPHARMA.NS
Diluted Average Shares,2021-03-31 00:00:00,,BALPHARMA.NS
Basic Average Shares,2021-03-31 00:00:00,,BALPHARMA.NS
Diluted EPS,2021-03-31 00:00:00,,BALPHARMA.NS
Basic EPS,2021-03-31 00:00:00,,BALPHARMA.NS
Diluted NI Availto Com Stockholders,2021-03-31 00:00:00,,BALPHARMA.NS
Net Income Common Stockholders,2021-03-31 00:00:00,,BALPHARMA.NS
Otherunder Preferred Stock Dividend,2021-03-31 00:00:00,,BALPHARMA.NS
Net Income,2021-03-31 00:00:00,,BALPHARMA.NS
Minority Interests,2021-03-31 00:00:00,,BALPHARMA.NS
Net Income Including Noncontrolling Interests,2021-03-31 00:00:00,,BALPHARMA.NS
Net Income Continuous Operations,2021-03-31 00:00:00,,BALPHARMA.NS
Tax Provision,2021-03-31 00:00:00,,BALPHARMA.NS
Pretax Income,2021-03-31 00:00:00,,BALPHARMA.NS
Other Non Operating Income Expenses,2021-03-31 00:00:00,,BALPHARMA.NS
Special Income Charges,2021-03-31 00:00:00,,BALPHARMA.NS
Other Special Charges,2021-03-31 00:00:00,543000.0,BALPHARMA.NS
Write Off,2021-03-31 00:00:00,0.0,BALPHARMA.NS
Net Non Operating Interest Income Expense,2021-03-31 00:00:00,,BALPHARMA.NS
Total Other Finance Cost,2021-03-31 00:00:00,16190000.0,BALPHARMA.NS
Interest Expense Non Operating,2021-03-31 00:00:00,,BALPHARMA.NS
Interest Income Non Operating,2021-03-31 00:00:00,3142000.0,BALPHARMA.NS
Operating Income,2021-03-31 00:00:00,,BALPHARMA.NS
Operating Expense,2021-03-31 00:00:00,,BALPHARMA.NS
Other Operating Expenses,2021-03-31 00:00:00,,BALPHARMA.NS
Depreciation And Amortization In Income Statement,2021-03-31 00:00:00,,BALPHARMA.NS
Amortization,2021-03-31 00:00:00,11881000.0,BALPHARMA.NS
Depreciation Income Statement,2021-03-31 00:00:00,,BALPHARMA.NS
Research And Development,2021-03-31 00:00:00,185000.0,BALPHARMA.NS
Selling General And Administration,2021-03-31 00:00:00,123945000.0,BALPHARMA.NS
Selling And Marketing Expense,2021-03-31 00:00:00,102690000.0,BALPHARMA.NS
General And Administrative Expense,2021-03-31 00:00:00,21255000.0,BALPHARMA.NS
Rent And Landing Fees,2021-03-31 00:00:00,6832000.0,BALPHARMA.NS
Gross Profit,2021-03-31 00:00:00,,BALPHARMA.NS
Cost Of Revenue,2021-03-31 00:00:00,,BALPHARMA.NS
Total Revenue,2021-03-31 00:00:00,,BALPHARMA.NS
Operating Revenue,2021-03-31 00:00:00,,BALPHARMA.NS
